1. Scrip
  2. >>Business

India's Claris plans $66 million IPO

 
• By Anju Ghangurde

Claris Lifesciences, an Indian sterile injectables firm, plans to raise up to Rs3 billion ($66.3 million) through an initial public offering to finance its expansion plans.

Claris Lifesciences, an Indian sterile injectables firm, plans to raise up to Rs3 billion ($66.3 million) through an initial public offering to finance its expansion plans.

Claris said that the offer of equity shares of Rs10 each is proposed through a book building process and that a price band of between Rs278 and Rs293 per share...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.